Introduction
The toxic side effects of psychotropic drugs are more frequently recognized today, and there have been many reports of the marrow, heart, liver, skin and eyes being affected (1, 3, 8, 11, 12) . The use of combinations of drugs has prompted particular concern because of their popularity as well as their tendency to produce unexpected reactions (2) .
This report covers the laboratory findings in a group of schizophrenic patients who took part in a 14-month drug study, with 8-week drug treatment periods separated by 8-week placebo periods (9) .
Material and Method
Twenty-two male chronic schizophrenic patients (16 white and 6 coloured) under 50 years of age were selected from various state hospital populations. Their average age was 33 years, average length of illness eight years, and average length of present hospitalization four years. They were divided into three groups at random, each group following a different medication sequence. The study was of a double-blind crossover design. The medications were made up in identical capsules and administered on a mg/kg body weight basis. The daily dose ranges were chlordiazepoxide, 60-100 mg; thioridazine, 3OQ-.500 mg; and a combination of chlordiazepoxide, 30-50 mg, and thioridazine, 150-250 mg. Other details of the structure, methodology, and clinical findings of the study are described elsewhere (6, 9) .
All patients were treated in the same ward of the Institute and were subject Canad. Psychiat. Ass, J. Vol. 14 (1969) to the same environmental and therapeutic effects for the total 14-month study period. No other medications, except paraldehyde or chloral hydrate, were used, and these only for disabling agitation and restlessness.
In each patient early morning blood samples were taken by the same personnel every four weeks. In sixteen of the more co-operative patients, laboratory tests were done every two weeks and a total and differential white cell count every week. Routine testing was performed on all samples for hemoglobin, hematocrit, ESR, SGOT, serum bilirubin, cephalin flocculation, alkaline phosphatase, cholesterol and urea nitrogen. U rinalysis was performed every week. All specimens were assessed by the same facilities and technicians througout the study.
The mean values were calculated for the two to three tests for each laboratory item during the last five weeks of each drug and placebo period. The significance of differences in the means between placebo and drug periods was determined by the two-tailed 't' test and the Wilcoxon test.
Results

Hemoglobin and Hematocrit:
The changes in values for hemoglobin and hematocrit from placebo to chlordiazepoxide and from chlordiazepoxide to placebo treatments were not statistically significant. There was a significant decrease in values from placebo to thioridazine treatment for hemoglobin and hematocrit at the < .01 and < .03 levels, respectively. The changes in values from thioridazine to placebo treatment were not significant. Values significantly decreased from placebo to combined medication treatment for both hemoglobin and hematocrit (P < .05) and increased 300 CANADIAN PSYCHIATRIC ASSOCIATION JOURNAL \Tol. 14,~o. 3 from combined medication to placebo treatment (P < .001 for hemoglobin; P < .01 for hematocrit).
White Cell Count: There were no statistical changes in white cell counts for any of the placebo to drug or drug to placebo periods.
SGOT jESR:
There was an average rise in SGOT of 7.3 units from placebo to combination treatment, with a fall from combination to placebo treatment. Changes in SGOT with chlordiazepoxide and thioridazine were variable and small. None of the changes were of statistical significance. There were no noteworthy changes in the ESR during any of the drug or placebo periods.
Cholesterol: All but one patient showed an increase in cholesterol from placebo to combined therapy, but the changes were small (average 17 mg%). Changes from combined therapy to placebo were more marked, with an average decrease of 65 mg% (P < .01).
From placebo to thioridazine there was an average decrease of 42 mg%, and from thioridazine to placebo an average decrease of 32 mg%. Neither of these changes were statistically significant. The changes with chlordiazepoxide were variable and small.
Blood Urea Nitrogen:
There were no significant changes in blood urea nitrogen during placebo or drug treatment.
Liver Function Tests:
The majority of values for serum bilirubin fell in each of the three different placebo to drug sequences and rose from each drug to placebo treatment. The decreases with chlordiazepoxide were not statistically significant, but value increases from chlordiazepoxide to placebo treatment were significant at the .02 level. The decreases from placebo to thioridazine treatment (P < .10) and increases from thioridazine to placebo treatment (P < .002) were the most consistent. The decreases in values from placebo to combined treatment showed no statistical differences, but the increases from combined treatment to placebo values were statistically significant (P < .02). The greatest individual decrease was 0.7 mg% from placebo to chlordiazepoxide treatment. One patient had an increase of 0.9 mg% from thioridazine to placebo treatment. The alkaline phosphatase and cephalin flocculation tests showed no statistical differences during any of the drug and placebo treatments.
Urinalysis:
No abnormalities were observed during any of the placebo or drug periods.
None of the laboratory deviations necessitated interruption or changes in drug dosages, and all values fell within the ranges of values derived from a control population in the Institute (7).
Discussion
The most striking individual findings in this study were shifts in the hemoglobin, hematocrit, bilirubin, and cholesterol values. Changes in hemoglobin and hematocrit with variations in psychosis ( 15) and with psychotropic drugs (4, 14) have been reported before. The mechanisms for this are unknown, but neuroendocrine changes or water retention and ionic shifts could be the cause.
Increases in cholesterol have been reported with other psychotropic drugs (10, 13, 16) , and the increase during combined treatment and the subsequent fall during placebo treatment would be in keeping with these findings.
It is difficult to interpret the shifts in serum bilirubin values, but they suggest that psychotropic drugs may influence bilirubin synthesis or breakdown. The variations in alkaline phosphatase and cephalin flocculation accompanying placebo and drug treatment were not significant enough to suggest liver disturbance.
The different physiological effects of chlordiazepoxide and thioridazine, singly and combined, could be related to contrasting hematological and biochemical changes induced by each drug. Certain positive trends were found and it was felt that an even more systematic study of larger numbers of values would have demonstrated more significant changes.
This study, therefore, suggests that a standardized methodology of collection and analysis of laboratory data can demonstrate different effects on laboratory values when drugs are given singly and in combination. Such techniques could provide evidence of the action of various psychotropic drugs, alone and in combination, on various body systems. The usefulness of regular monitoring of laboratory values can be increased further by computer methods, particularly when large numbers of patients are involved. We have already described the advantages of such methods (5) .
